Daily Stock Analysis, ILMN, Illumina Inc, priceseries

Illumina Inc. Daily Stock Analysis
Stock Information
Open
445.00
Close
447.01
High
453.92
Low
443.50
Previous Close
449.92
Daily Price Gain
-2.91
YTD High
555.77
YTD High Date
Feb 12, 2021
YTD Low
356.00
YTD Low Date
Jan 11, 2021
YTD Price Change
79.25
YTD Gain
21.55%
52 Week High
555.77
52 Week High Date
Feb 12, 2021
52 Week Low
260.42
52 Week Low Date
Sep 21, 2020
52 Week Price Change
151.51
52 Week Gain
51.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
131.13
Jan 30. 2017
157.03
18 Trading Days
19.75%
Link
LONG
Dec 28. 2017
217.52
Jan 29. 2018
238.83
20 Trading Days
9.80%
Link
LONG
Mar 5. 2018
230.88
Mar 21. 2018
248.53
12 Trading Days
7.64%
Link
LONG
May 4. 2018
244.82
May 25. 2018
264.95
15 Trading Days
8.22%
Link
LONG
Jul 6. 2018
286.13
Jul 27. 2018
305.01
15 Trading Days
6.60%
Link
LONG
Jun 4. 2019
313.83
Jul 11. 2019
367.34
26 Trading Days
17.05%
Link
LONG
Nov 15. 2019
305.99
Dec 11. 2019
322.04
17 Trading Days
5.25%
Link
LONG
Apr 6. 2020
278.01
May 1. 2020
311.08
18 Trading Days
11.90%
Link
LONG
May 15. 2020
335.00
Jun 3. 2020
358.71
12 Trading Days
7.08%
Link
LONG
Nov 27. 2020
317.03
Jan 11. 2021
368.21
29 Trading Days
16.14%
Link
LONG
Jan 15. 2021
376.35
Feb 3. 2021
424.17
12 Trading Days
12.71%
Link
LONG
Feb 4. 2021
428.64
Feb 22. 2021
473.70
11 Trading Days
10.51%
Link
LONG
May 18. 2021
386.36
Jul 8. 2021
466.60
35 Trading Days
20.77%
Link
Company Information
Stock Symbol
ILMN
Exchange
NasdaqGS
Company URL
http://www.illumina.com
Company Phone
8582024500
CEO
Francis A. deSouza
Headquarters
California
Business Address
5200 ILLUMINA WAY, SAN DIEGO, CA 92122
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001110803
About

Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing services. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illumina's BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.